Phase II Study Testing a Cancer Vaccine Combined With Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Led by Centre Hospitalier Universitaire de Besancon · Updated on 2026-03-16
105
Participants Needed
14
Research Sites
100 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of a CD4 helper T-inducer cancer vaccine called UCPVax with anti-PD-L1 therapy atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinoma HCC. This randomized Phase II trial aims to determine the clinical interest and immune response effectiveness by measuring the objective response rate at 6 months. The study involves 105 patients across 10 centers and is sponsored by the Centre Hospitalier Universitaire de Besancon.
Participants are assigned to one of two groups one receiving atezolizumab plus bevacizumab combined with the UCPVax vaccine, and the other receiving only atezolizumab plus bevacizumab. Atezolizumab is given intravenously at 1200 mg every 3 weeks, bevacizumab at 15 mgkg every 3 weeks, and UCPVax vaccine is administered subcutaneously at 0.5 mg with an adjuvant. Treatment continues until disease progression or unacceptable side effects occur.
During the study, patients will undergo regular assessments to evaluate tumor response using mRECIST guidelines at 6 months. Researchers will also monitor overall survival, progression-free survival, and disease control rate over approximately 2 years. Safety is closely followed through monitoring for adverse events and treatment tolerance. Participants overall health, performance status, and liver function will be evaluated throughout the study period.
CONDITIONS
Brief Title
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Research Team
B
Borg Christophe, Pr
A
Angélique VIENOT, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Signed informed consent
Histologically confirmed hepatocellular carcinoma
Locally advanced, metastatic, or unresectable disease
No previous systemic anti-cancer treatment
Age 18 years or older
Measurable disease according to mRECIST guidelines
Recovery from previous chemoembolization, radioembolization, or radiotherapy to grade 1 or less toxicity (except grade 2 alopecia)
Performance status less than 2
Child-Pugh Class A liver function
BCLC C stage or BCLC B stage not eligible for loco-regional therapy
You will not qualify if you...
Prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA4, or other immune therapies
Diagnosis of another malignancy within 3 years except treated basal cell carcinoma or certain cervical or breast cancers
Medical or psychiatric conditions making participation inappropriate
Current participation in another investigational study
Under guardianship, curatorship, or legal protection
Fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
Uncontrolled pleural effusion, pericardial effusion, ascites, or symptomatic fistula
Uncontrolled tumor-related pain requiring corticosteroids or frequent hospitalizations
Active central nervous system metastases or carcinomatous meningitis (stable treated brain metastases allowed)
History of encephalopathy
Recent bleeding from untreated or incompletely treated esophageal or gastric varices within 6 months
Inadequate organ function such as unstable heart failure, respiratory failure, uncontrolled infection, or other life-risk conditions
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Repeated 3-week cycles until disease progression or discontinuation
Participants receive Atezolizumab and Bevacizumab intravenously every 3 weeks. Participants in the experimental arm also receive the UCPVax vaccine subcutaneously. Treatment continues until disease progression or unacceptable toxicity.
Infusions every 3 weeks; vaccine injections as scheduled
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating 18F-FDGal PETCT and PETMRI for Diagnosis and Treatment Monitoring in Adults with Hepatocellular Carcinoma
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Phase 2 Study of 68Ga-PSMA-11 PET-Guided Radioligand Therapy with 177Lu-PSMA-617 in Adults with Metastatic Hepatocellular Carcinoma
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Open Label Study Evaluating BAY 3547926 Safety and Activity in Advanced Hepatocellular Carcinoma Patients
Comparing MRI, CT, and Two PET Scans 18F-FDGal and 18F-choline for Diagnosing Hepatocellular Carcinoma in Adults
Study on Using Pre-treatment Tumor Biopsies to Predict Response to PD-1PD-L1 Immunotherapy in Various Cancers
National Phase II Study of Proton Therapy for Hepatocellular Carcinoma in Adults
Aiming to Improve Treatment Safety and Outcomes by Reducing Liver Radiation Exposure
Phase I Study of Safety and Effects of GC001 Oncolytic Virus Injection in Adults with Advanced Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto...